Cancer Proteomics Group

Prof. Richard Christopherson

Left-right: Dr Larissa Belov, Prof Richard Christopherson, Dr Ben Crossett (SUPRU), Munther Alomari (PhD), Duthika Mallawaaratchy (PhD), Jerry Zhou (PhD), Kieran

Matic (Honours), Yiping Che (PhD), Dr Kim Kaufman, Trisha Almazi (PhD)Missing: Dr Swetlana Mactier, Erin Sykes (PhD).

Colorectal cancer (CRC)LeukaemiaMelanomaGlioblastoma (GBM)

Cancers we study:

Identification of proteome changes in cancer cells after treatment with a drug such as:

◦ Purine analogues (e.g., fludarabine) ◦ HSP90 inhibitors (e.g., SNX-7081)◦ ER-stress inducers (e.g., thapsigargin)

Understand mechanisms of drug action and resistance, identification of new drug targets

Anti-cancer drugs

DotScan™ CD antibody microarrays◦ Capture live cells and obtain a surface profile

(disease signature, immunophenotype)◦ In collaboration with major NSW hospitals, we

have collected and tested many different clinical samples, including:

Leukaemias Colorectal cancers Metastatic melanoma

◦ To improve disease stratification, prognostication and prediction of response to treatment

Cell surface markers

Stage III melanoma Survival analyses – prognostic biomarkers good versus poor prognosis groups with

identical stage cancers

Glioblastoma multiformeSerial lesions, pre and post chemotherapy, biomarkers for chemo-resistance

Chronic lymphocytic LeukaemiaStable vs progressive disease course

Comprehensive, quantitative clinical proteomics

Clinical samples and cell lines In vitro chemotherapy treatment Flow cytometry Sub-cellular proteome isolation

◦ Cytosol, nucleus, mitochondria and plasma membrane Mass Spectrometry and gel-based analyses

(SUPRU) Quantitative analysis

◦ DIGE, iTRAQ, SRM and label-free methods

Techniques

Thank you!

Christopherson lab